Biogen Inc. and Alloy Therapeutics Inc. announced a collaboration and license agreement to use Alloy’s proprietary AntiClastic™ antisense oligonucleotide platform for the development of new antisense therapeutics targeting undisclosed disease areas.
The agreement grants Biogen access to the AntiClastic platform, which is engineered to improve delivery and potency of antisense drugs. Alloy will receive an upfront payment and will be eligible for milestone payments; the specific amounts were not disclosed in the announcement.
This partnership expands Biogen’s antisense pipeline beyond its traditional multiple sclerosis franchise and supports its strategy to diversify into rare neurology and immunology. Biogen’s 2025 revenue totaled $9.9 billion, a 2% increase from 2024, but Q4 2025 revenue fell 7% year‑over‑year. New products such as LEQEMBI, SKYCLARYS, and ZURZUVAE have offset declines in the MS franchise, yet the company projects a mid‑single‑digit revenue decline in 2026 due to continued erosion of legacy MS products and a $34 million charge in Q1 2026 that will reduce EPS by approximately $0.19.
Alloy’s AntiClastic platform is designed to overcome historical challenges in antisense therapy, such as limited biodistribution and therapeutic index. Biogen already has experience with antisense technology through its approved SMA drug Spinraza and an investigational tau‑targeting ASO for Alzheimer’s disease. The collaboration positions Biogen to accelerate next‑generation antisense therapies and strengthen its competitive position in the growing antisense market.
Investors have expressed caution regarding Biogen’s strategic transition. Concerns include the company’s shift away from legacy multiple sclerosis products, the anticipated R&D charge for Q1 2026, and the $5.6 billion acquisition of Apellis Pharmaceuticals, which has raised questions about short‑term dilution and investment costs.
The collaboration signals Biogen’s commitment to expanding its antisense portfolio and leveraging Alloy’s technology, while short‑term financial headwinds remain as the company navigates its broader strategic pivot.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.